Johnson c Johnson Cougar biotechnology inc. leading the acquisition of man-in-the-promising results in treating prostate cancer huge success seems to be. In the second half of 2010, J & J in its aborted the clinical phase III candidate in its novel drugs, abiraterone acetate is analyst Cougar biotechnology, scientists have studied originally by. It is well known that Dr. Lindsay Rosenwald, an expert in the field of biotechnology, his team and invest with the first trial of abiraterone in phase. Abiraterone clinical of the first great success and showed promising results; Therefore, Lindsay Rosenwald Cougar biotechnology funds and indirectly this can also involve steps using Johnson of Johnson by promoting the development of more arguments. Interim analysis of phase III, demonstrated good results because it is a public company data, and patient care to take placebo allow abiraterone suggested. October, the company released the exact number and time abiraterone can extend life. This data will take place at the Milan Conference will be shared in science. If drug a statistically significant survival in prostate cancer patients, this approval get enough, sanofi-aventis provides Taxotere treatment failure that man, given the poor prognosis, abiraterone.
Sano file other drugs, Cabazitaxel for application marketing. However, it is still difficult to compare the drug abiraterone and. Cabazitaxel treatment patients median 15.1 months lived. About that time Novantrone, OSI Pharmaceuticals and EMD Serono to compare the products. J c J its abiraterone plus steroids prednisone treatment prednisone hand comparison alone.
It's Provenge (approximately by Dendreon) sales are in fact impact since any drug hits the leading position would care. Drug immune system have been developed with the support of the disease, of whom their hormone treatment despite ongoing castration-resistant prostate cancer patients are commonly used in. Both of these drugs to treat their patients, Taxotere fails, you're going to be used when. Provenge too in this case, most likely to be used.
Prostate cancer treatment is very difficult, it is considered a disease since abiraterone for patients can be a good option. Investors, Lindsay Rosenwald, MD, as already the drug's potential clients to discover and it's research and male prostate cancer survival chance to give more to invest in development.
Tidak ada komentar:
Posting Komentar